372.62

1.09% +4.025

Argen X SE ADR (ARGX)

Overview News Price History Option Chain Why ARGX Down? Discussions Forecast

Argen X SE ADR stock is currently priced at $372.62, with a 24-hour trading volume of 154.87K. It has seen a +1.09% increased in the last 24 hours and a -6.27% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $371.2 pivot point. If it approaches the $375.2 resistance level, significant changes may occur.

Previous Close:

$368.60

Open:

$370.815

24h Volume:

154.87K

Market Cap:

$22.28B

Revenue:

$1.23B

Net Income/Loss:

$-295.05M

P/E Ratio:

-89.57

EPS:

-4.16

Net Cash Flow:

$-910.55M

1W Performance:

+3.44%

1M Performance:

-6.27%

6M Performance:

-20.79%

1Y Performance:

-2.67%

1D Range:

$366.72

$375.80

52W Range:

$327.73

$550.76

Argen X SE ADR Stock (ARGX) Company Profile

Name

Argen X SE ADR

Sector

Healthcare (1203)

Industry

Biotechnology (688)

Phone

31763030488

Address

Willemstraat 5, Breda

Employee

Twitter

Next Earnings Date

Latest SEC Filings

ARGX's Discussions on Twitter

Argen X SE ADR Stock (ARGX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Dec-20-23	Downgrade	Deutsche Bank	Buy → Hold
Dec-20-23	Downgrade	William Blair	Outperform → Mkt Perform
Jul-31-23	Initiated	Scotiabank	Sector Perform
Jul-24-23	Downgrade	UBS	Buy → Neutral
Jul-17-23	Resumed	Evercore ISI	Outperform
Jun-15-23	Initiated	Societe Generale	Sell
May-31-23	Initiated	UBS	Buy
Apr-25-23	Initiated	Citigroup	Buy
Mar-14-23	Upgrade	Robert W. Baird	Neutral → Outperform
Dec-07-22	Initiated	William Blair	Outperform
Oct-12-22	Initiated	Oppenheimer	Perform
Jul-29-22	Downgrade	Robert W. Baird	Outperform → Neutral
Jun-28-22	Resumed	Stifel	Buy
May-03-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Dec-08-21	Initiated	Wells Fargo	Overweight
Nov-29-21	Upgrade	Piper Sandler	Neutral → Overweight
Oct-29-21	Upgrade	Guggenheim	Neutral → Buy
Oct-28-21	Upgrade	Raymond James	Outperform → Strong Buy
Oct-07-21	Initiated	Jefferies	Buy
Sep-23-21	Upgrade	Redburn	Neutral → Buy
Sep-07-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jul-23-21	Initiated	Deutsche Bank	Hold
Jul-19-21	Resumed	Wolfe Research	Outperform
Jun-18-21	Initiated	UBS	Buy
Jun-04-21	Resumed	Robert W. Baird	Outperform
May-10-21	Upgrade	H.C. Wainwright	Neutral → Buy
Apr-23-21	Initiated	Redburn	Neutral
Mar-05-21	Reiterated	H.C. Wainwright	Neutral
Feb-02-21	Downgrade	Piper Sandler	Overweight → Neutral
Jan-04-21	Downgrade	Guggenheim	Buy → Neutral
Aug-25-20	Initiated	Raymond James	Outperform
Aug-19-20	Downgrade	Evercore ISI	Outperform → In-line
Jul-29-20	Initiated	H.C. Wainwright	Neutral
Feb-10-20	Initiated	BofA/Merrill	Buy
Nov-05-19	Initiated	Credit Suisse	Neutral
Oct-31-19	Upgrade	William Blair	Mkt Perform → Outperform
Oct-22-19	Initiated	JP Morgan	Overweight
Sep-27-19	Initiated	Wells Fargo	Market Perform
Sep-16-19	Resumed	Cowen	Outperform
Jun-28-19	Initiated	Robert W. Baird	Outperform
Jan-18-19	Resumed	SunTrust	Buy
Jan-04-19	Initiated	Morgan Stanley	Overweight
Dec-17-18	Initiated	Goldman	Buy
Dec-14-18	Initiated	Wolfe Research	Outperform
Jun-29-18	Initiated	Nomura	Buy
Apr-09-18	Initiated	SunTrust	Buy
Jan-29-18	Reiterated	JMP Securities	Mkt Outperform

View All

Argen X SE ADR Stock (ARGX) Latest News

argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease

GlobeNewswire Inc.

Argen X SE ADR Stock (ARGX) Financials Data

Argen X SE ADR (ARGX) Revenue 2024

ARGX reported a revenue (TTM) of $1.23 billion for the quarter ending December 31, 2023, a +198.56% rise year-over-year.

Argen X SE ADR (ARGX) Net Income 2024

ARGX net income (TTM) was -$295.05 million for the quarter ending December 31, 2023, a +58.42% increase year-over-year.

Argen X SE ADR (ARGX) Cash Flow 2024

ARGX recorded a free cash flow (TTM) of -$910.55 million for the quarter ending June 30, 2023.

Argen X SE ADR (ARGX) Earnings per Share 2024

ARGX earnings per share (TTM) was -$5.15 for the quarter ending December 31, 2023, a +60.75% growth year-over-year.

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Staten Biotechnology B.V.; and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.